Toll-Like Receptor 3抗体;Toll-Like Receptor 3 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using M6PR mouse mAb against mouse brain (1) and HepG2 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using M6PR mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using M6PR mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain tissues using M6PR mouse mAb with DAB staining.    

  
  

Toll-like receptor 3 (TLR3) is a transmembrane protein belonging to the Toll-like receptor family, which plays a critical role in the innate immune system by recognizing pathogen-associated molecular patterns (PAMPs). TLR3 specifically detects double-stranded RNA (dsRNA), a molecular signature of viral infections, and triggers downstream signaling pathways to induce inflammatory cytokines and type I interferons. This receptor is expressed in immune cells (e.g., dendritic cells) and epithelial cells, and its activation is implicated in antiviral responses, autoimmune disorders, and cancer immunology.

TLR3 antibodies are essential tools for studying the receptor's expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to quantify TLR3 levels in tissues or cell lines. Additionally, TLR3-specific antibodies can modulate receptor activity; some act as agonists to mimic dsRNA binding and stimulate immune responses, while others serve as antagonists to inhibit excessive inflammation in autoimmune diseases.

Research involving TLR3 antibodies has advanced our understanding of viral infections (e.g., influenza, hepatitis C), neuroinflammatory conditions, and TLR3-related genetic disorders. These antibodies also hold therapeutic potential, such as in cancer immunotherapy to enhance antitumor immunity or as adjuvants in vaccine development. However, challenges remain in optimizing antibody specificity and minimizing off-target effects. Overall, TLR3 antibodies are pivotal in bridging mechanistic studies and clinical applications targeting innate immunity.